Post installation acceptance testing is vital to demonstrate that the equipment meets the vendor's specification and is suitable for clinical studies. The test procedures described in the NEMA NU 2-2001 document form the basis of vendor performance specifications of PET scanners and hence are also appropriate for acceptance testing. Initial installation performance tests of the Philips Gemini GXL PET/CT scanner installed at Liverpool Hospital revealed that the peak noise equivalent count rate (NECR) measurement of 57.5 kcps was substantially lower than the specification of 70 kcps and the scatter fraction of 38.5% was 10% higher than the specification of

No abstract

No abstract

Background: 4-(N-(S-glutathionylacetyl)amino) phenylarsonous acid (GSAO) when conjugated at the γ-glutamyl residue with fluorophores and radio-isotopes is able to image dead and dying cells in vitro and in vivo by binding to intracellular 90-kDa heat shock proteins (hsp90) when cell membrane integrity is compromised. The ability to image cell death has potential clinical impact especially for early treatment response assessment in oncology. This work aims to assess the biodistribution and tumour uptake of diethylene triamine pentaacetic acid GSAO labelled with 111 In ([ 111 In]In-DTPA-GSAO) and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid GSAO labelled with 67 Ga ([ 67 Ga]Ga-DOTA-GSAO) in a murine subcutaneous tumour xenograft model and estimate dosimetry of [ 67 Ga]Ga-DOTA-GSAO. Results: There was good tumour uptake of both [ 111 In]In-DTPA-GSAO and [ 67 Ga]Ga-DOTA-GSAO (2.44 ± 0.26% injected activity per gramme of tissue (%IA/g) and 2.75 ± 0.34 %IA/g, respectively) in Balb c nu/nu mice bearing subcutaneous tumour xenografts of a human metastatic prostate cancer cell line (PC3M-luc-c6). Peak tumour uptake occurred at 2.7 h post injection. [ 111 In]In-DTPA-GSAO and [ 67 Ga]Ga-DOTA-GSAO demonstrated increased uptake in the liver (4.40 ± 0.86 %IA/g and 1.72 ± 0.27 %IA/g, respectively), kidneys (16.54 ± 3.86 %IA/g and 8.16 ± 1.33 %IA/g) and spleen (6.44 ± 1.24 %IA/g and 1.85 ± 0.44 %IA/g); however, uptake in these organs was significantly lower with [ 67 Ga]Ga-DOTA-GSAO (p = 0.006, p = 0.017 and p = 0.003, respectively). Uptake of [ 67 Ga]Ga-DOTA-GSAO into tumour was higher than all organs except the kidneys. There was negligible uptake in the other organs. Excretion of [ 67 Ga]Ga-DOTA-GSAO was more rapid than [ 111 In]In-DTPA-GSAO. Estimated effective dose of [ 67 Ga]Ga-DOTA-GSAO for an adult male human was 1.54 × 10 − 2 mSv/MBq. Conclusions: [ 67 Ga]Ga-DOTA-GSAO demonstrates higher specific uptake in dead and dying cells within tumours and lower uptake in normal organs than [ 111 In]In-DTPA-GSAO. [ 67 Ga]Ga-DOTA-GSAO may be potentially useful for imaging cell death in vivo. Dosimetry estimates for [ 67 Ga]Ga-DOTA-GSAO are acceptable for future human studies. This work also prepares for development of 68 Ga GSAO radiopharmaceuticals.

No abstract

No abstract

No abstract